TARGET临床试验方案:前列腺癌靶向联合病灶周围活检对比靶向联合系统活检
TARGET是一项前瞻性多中心开放标签比较试验,每例患者自身对照,均接受靶向、病灶周围及系统三种活检。主要终点为靶向+病灶周围方案对比靶向+系统方案检测临床显著前列腺癌(GG≥2)的敏感度和特异度。
要点
- 靶向+病灶周围活检可能保持csPC检出率并减少低危GG1检出。
- 每例患者自身对照,均接受靶向、病灶周围和系统三种活检。
- 主要终点为两种活检方案检测csPC的敏感度和特异度。
核心结论
- 尚待试验结果确定靶向+病灶周围方案能否在保持csPC检出率的同时减少GG1检出。
研究设计与样本
- TARGET为前瞻性、多中心、开放标签、比较性临床试验,每例患者自身对照并接受靶向、病灶周围和系统三种活检。
- 入选期21个月,每例患者参与时长3个月。
主要发现
- 主要终点为靶向+病灶周围方案对比靶向+系统方案检测csPC(GG≥2)的敏感度和特异度。
- 次要终点包括实验方案与标准方案对无意义PC(GG1)和侵袭性PC(GG≥3)检出率的差异。
关键数值与推荐
- csPC常用Gleason分级分组(GG)≥2定义。
临床怎么用
- 若试验达到主要终点,靶向+病灶周围活检可能作为减少过度诊断的采样策略。
局限性
- 主要局限性为开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Multiparametric magnetic resonance imaging (mpMRI) with targeted biopsies improves detection of clinically significant prostate cancer (csPC), commonly defined as Gleason grade group (GG) ≥2. Current practice combines targeted and systematic biopsies, which increases csPC detection but also increases detection of insignificant PC (GG 1), which contributes to overdiagnosis. Perilesional sampling around MRI-visible lesions has been proposed as a strategy to mitigate targeting imprecision while limiting sampling outside the MRI lesion area and GG 1 detection. The primary objective is to determine the diagnostic performance of the experimental targeted + perilesional biopsy scheme for detection of csPC in comparison to the standard targeted + systematic biopsy scheme. CLINICAL TRIAL DESIGN AND TIMEFRAME: TARGET is a prospective, multicentre, open-label, comparative clinical trial. Each patient acts as their own control, as each patient will undergo all three types of biopsy (targeted, perilesional, and systematic). The inclusion period will last for 21 mo, and the participation duration for each patient is 3 mo. ENDPOINTS: The primary endpoint is the sensitivity and specificity of the targeted + perilesional scheme for csPC detection in comparison to the targeted + systematic scheme. Secondary endpoints include differences in the detection rate for insignificant PC (GG 1) and aggressive PC (GG ≥3) between the experimental and standard biopsy schemes. DATA SOURCES AND STATISTICAL ANALYSIS PLAN: The data collected will include patient demographics and laboratory, radiology, and pathology reports. Analyses will be performed with SAS version 9.4 using a locked database. STRENGTHS AND LIMITATIONS: Strengths include the prospective and multicentre design. The main limitation is the open-label design. FUNDING: TARGET is funded by Ramsay Générale de Santé (Paris, France), and supported by the Prostate Cancer Committee of Association Française d'Uologie. ETHICS AND TRIAL REGISTRATION: The trial was assessed by the CPP Ouest VI ethics committee and is registered on ClinicalTrials.gov as NCT07296042. PATIENT SUMMARY: Our multicentre trial is comparing two different approaches for prostate biopsy to determine if sampling the area around lesions seen on an MRI (magnetic resonance imaging) scan can maintain the detection rate for clinically significant prostate cancer while reducing detection of low-risk disease.
引用
- Baboudjian M, Sordelli F, Patard JJ, et al. Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol. Eur Urol Oncol. 2026. PMID: 41813528. doi:10.1016/j.euo.2026.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。